Molecular genetics of megakaryocytic leukaemia

Molecular genetics of megakaryocytic leukaemia

Project details

Megakaryocytic leukaemia and myeloproliferative diseases (MPN) are malignant blood cell diseases involving deregulation of megakaryocytes and platelets. Both diseases are in need of improved treatments. 

The relatively rarity of megakaryocytic leukaemia and the fact that it arises in very scarce specialised bone marrow cells (the platelet-producing megakaryocytes) mean that the biological characteristics and molecular changes, as well as treatment optimisation, are not well understood. 

In this project molecular genetics and genomics approaches will be employed to better model and understand the molecular changes driving the establishment and maintenance of megakaryocytic leukaemia and MPN. 


About our research group

Our laboratory focuses on understanding the molecular regulation of blood cell production and function in healthy individuals as well as defining the changes in the regulatory mechanisms that cause diseases such as leukaemia, inflammation and autoimmunity. 

Discovery and functional dissection of molecules that control megakaryocyte development and the application of genetics and genomics tools for defining the molecular genetics of leukaemia have been core activities of the laboratory for many years. Recent relevant publications include: Ng, PLoS Genet. 2015 11(5):e1005211; Ng, Proc Natl Acad Sci USA. 2014 111(16):5884.



Professor Warren Alexander

Professor Warren Alexander in the lab
Joint Division Head

Project Type: